Press Release

BME submits entries from Vytrus, Sngular, Arteche and Opdenergy for the European Small and Mid-Cap Awards

31 May, 2023

Sarah Harmon (Sngular), Luis Cid (Opdenergy), Cristina Ordóñez (Arteche) y Albert Jané (Vytrus)

  • The awards, organised by the European Commission, EuropeanIssuers and FESE, aim to increase the visibility of small and medium-sized listed companies

Four Spanish companies, three from BME Growth (Vytrus, Sngular and Arteche) and one from the main market (Opdenergy) will compete for the European Small and Mid-Cap Awards. The nominations, presented by BME, were announced today during the second day of the Medcap Forum, the benchmark meeting between investors and small and medium-sized Spanish listed companies. The event was attended by more than 120 investors, 25% international, and 110 companies.

The European Small and Mid-Cap Awards, which since 2013 have sought to recognize best practices and promote access to financial markets for smaller companies, are organized by the European Commission, EuropeanIssuers and the Federation of European Stock Exchanges (FESE). This year's awards will be presented in Bilbao in November.

Vytrus is a candidate in the Rising Star category. The company, which is dedicated to the development, production and marketing of high value-added active ingredients in the dermo-cosmetic sector and which debuted on BME Growth in March last year, has a capitalization of 22 million euros. In its first year as a listed company, it recorded a 98% revaluation, despite the geopolitical situation and stock market instability in 2022. Last year it increased revenues by 31%, EBITDA by 30% and net profit by 34%. 

Sngular, whose core business is the design, development, deployment and promotion of technology-based transformation projects and new digital products, will compete for the award in the Star of 2023 category. Sngular's 2022 figures demonstrate a model of steady growth. Its revenues have increased by 55% compared to the previous year, with a strong international presence, as a third of its revenues come from outside Spain. Ebitda has increased by 47% and 440 new professionals have joined the workforce. It has experienced a 32% increase in its price and reached a capitalization at the end of 2022 of 213 million euros.

Arteche is a candidate in the Star of Innovation category. The company, created in 1946 and present in 175 countries, has a capitalization of 222 million euros. It operates in the electricity sector, from generation to distribution, and specialises in the electrical equipment, components and solutions industry. Innovation in Arteche is a strategic variable, a corporate value and an internal commitment, also towards its customers.  In 2022, it has assigned 185 people to R&D, distributed geographically in 6 centres and 197,000 working hours. Its priority is to achieve an energy transmission and distribution network that enables the efficient, reliable and sustainable integration associated with the energy transition.  In 2022, it increased its sales by 22.6% to €346 million and improved its Ebitda by 12.4%.

Finally, Opdenergy is a candidate for the International Star award. The company, which made its IPO in July last year, is an independent renewable energy producer focused on solar photovoltaic and onshore wind energy production. Opdenergy is a multi-local and multi-technology company currently present in 9 OECD countries: Spain, Italy, USA, France, Chile, UK, Poland, Mexico and Colombia. It has local offices in Spain (company headquarters), Italy, UK, Mexico, Chile and USA. It has a market capitalization of 555 million euros.

The third and final day of the XIX Medcap Forum will be held tomorrow. In addition to private meetings and Discovery meetings between companies and investors, the day's programme includes two panels: "The new environment for Fixed Income and corporate finance", which will start at 10am, and "The IPO: a challenge in the life of a company". You can follow the panels live and consult all the information about the event on its website.

Copyright® BME 2024
[ ]